[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100414753":3},{"organization":4,"outcomesModule":7,"designInfo":28,"detailedDescription":27,"studyPopulation":27,"armGroups":35,"interventions":42,"overallOfficials":27,"centralContacts":47,"locations":54,"responsibleParty":89,"collaborators":27,"id":91,"slug":27,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":92,"sex":98,"minAge":99,"maxAge":27,"enrollmentInfo":100,"targetDuration":27,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":27,"overallStatus":75,"whyStopped":27,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"Centre Antoine Lacassagne","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":27},[9],{"measure":10,"description":11,"timeFrame":12},"early toxicities occuring until 6 months after performing per-operative radiotherapy","pourcentage of patient with toxicities of grade 3 and more (by CTCAE v5.0) related to per-operative radiotherapy and that occured until 6 months after performing","up to 6 months",[14,18,21,24],{"measure":15,"description":16,"timeFrame":17},"global tolerance of per-operative radiotherapy","global safety (assessed by CTCAE V5.0) of per-operative radiotherapy","up to 5 years",{"measure":19,"description":20,"timeFrame":17},"local disease free survival at 5 years of per-operative radiotherapy","To evaluate local disease free survival at 5 years of per-operative radiotherapy",{"measure":22,"description":23,"timeFrame":17},"disease free survival at 5 years of per-operative radiotherapy","To evaluate disease free survival at 5 years of per-operative radiotherapy",{"measure":25,"description":26,"timeFrame":12},"quality of life of patients","QLQ-C30 and QLQ BR-23 EORTC questionnaires",null,{"allocation":29,"interventionModel":30,"interventionModelDescription":31,"primaryPurpose":32,"observationalModel":27,"timePerspective":27,"maskingInfo":33},"NA","SINGLE_GROUP","radiotherapy treatment","TREATMENT",{"masking":34,"maskingDescription":27,"whoMasked":27},"NONE",[36],{"label":37,"type":38,"description":39,"interventionNames":40},"Per-Operative Radiotherapy technique by Papillon +TM","EXPERIMENTAL","Per-Operative Radiotherapy (1x20Gy) technique by Papillon +TM",[41],"Radiation: Per-Operative Radiotherapy technique by Papillon +TM",[43],{"type":44,"name":37,"description":45,"armGroupLabels":46,"otherNames":27},"RADIATION","20Gy Per-Operative Radiotherapy technique by Papillon +TM, on localized breast cancer",[37],[48],{"name":49,"role":50,"phone":51,"phoneExt":52,"email":53},"Frédérique JACQUINOT","CONTACT","04 92 03 10 24","+33","drci-promotion@nice.unicancer.fr",[55,74],{"facility":56,"status":57,"city":58,"state":27,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Pôle Santé République","NOT_YET_RECRUITING","Clermont-Ferrand","63000","France","FR",{"type":63,"coordinates":64},"Point",[65,66],3.08682,45.77969,{"lat":66,"lon":65},[69,71],{"name":70,"role":50,"phone":27,"phoneExt":27,"email":27},"Annie ITIE",{"name":72,"role":73,"phone":27,"phoneExt":27,"email":27},"Vivien FUNG, Dr","PRINCIPAL_INVESTIGATOR",{"facility":5,"status":75,"city":76,"state":27,"zip":77,"country":60,"countryCode":61,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"RECRUITING","Nice","06189",{"type":63,"coordinates":79},[80,81],7.26608,43.70313,{"lat":81,"lon":80},[84,87],{"name":85,"role":50,"phone":86,"phoneExt":52,"email":27},"Damien CHAUVIERE","0492031365",{"name":88,"role":73,"phone":27,"phoneExt":27,"email":27},"Marie-Eve FOUCHE-CHAND, Dr",{"type":90,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100414753",false,"NCT04680715","Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer","Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer : Faisability and Toxicity Study","RPOS+2","Inclusion Criteria:\n\n* Patient with invasive ductal adenocarcinoma \\\u003C=2cm, evaluate on all radiological exams;\n* Women aged 65 years or older (patients 65 years of age in the year may be included);\n* Grade 1 or 2 unifocal adenocarcinoma, all index KI67, positive HR, negative HER2 status;\n* T0 or T1, N0 radio-clinic;\n* Operable patient with breast volume compatible with conservative surgery;\n* Patient with prior malignancy or other concurrent malignancies are eligible, including bilateral breast cancer\n* Patients who have been made aware of the information sheet and have given their written signed informed consent;\n* Patients benefitting from social health insurance coverage\n\nExclusion Criteria:\n\n* Age less than 65 years (except if 65 years obtained during the year)\n* Patient with an exclusive in situ carcinoma\n* Patient with lymphatic invasion \u002F peri-nerve involvement \u002F vascular emboli\n* Patient with a lobular adenocarcinoma\n* Patient with metastatic disease\n* Multifocal tumor\n* Patient with grade 3 or N+ disease\n* N1 proved by ultrasound guided\n* patient unable to express her consent\n* Patient deprived placed under the authority of a tutor\n* Female patients who are pregnant or breastfeeding\n* Vulnerable patient: as defined in article L1121-5 à -8","FEMALE","65 Years",{"count":101,"type":102},40,"ESTIMATED","INTERVENTIONAL",[105],"PHASE2","Phase II study; open recruitment, multicentrique. The aim of this clinical research is to evaluate faisability and toxicity of the per-operative radiotherapy using PAPILLON + TM device for localized breast cancers patients over 65 years.",[108],"Localized Breast Cancer","2026-01-28",{"date":111,"type":112},"2026-01-29","ACTUAL",{"date":114,"type":112},"2021-07-16",{"date":116,"type":102},"2028-06",{"name":5,"class":6},2]